Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

Rhea-AI Summary

Onconova Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, at the Sofitel Hotel, New York. CEO Steven Fruchtman will present a corporate overview, followed by a 10-minute analyst-led fireside chat at 12:00 p.m. ET. The presentation will be available online and archived for 90 days. Onconova is focused on developing novel cancer treatments, including the multi-kinase inhibitor narazaciclib and rigosertib for KRAS+ non-small cell lung cancer.

NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY.

Steven Fruchtman, M.D., President & CEO of Onconova, will present a corporate overview to include an update on the company’s portfolio, followed by a 10-minute analyst-led fireside chat, on September 29^th, 2022, at 12:00 p.m. ET. The presentation can be viewed here or on the “Corporate Events and Presentations” section of the Onconova website and will be archived for 90 days. Dr. Fruchtman and other members of the Onconova management team will also be available for in-person one-on-one meetings during the conference on September 29^th, 2022. Those interested in requesting a meeting should contact their Ladenburg Thalmann representative.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company Contact:
Mark Guerin
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

When is Onconova's presentation at the Ladenburg Thalmann 2022 Healthcare Conference?

Onconova's presentation is scheduled for September 29, 2022, at 12:00 p.m. ET.

Who will present for Onconova at the conference?

Steven Fruchtman, M.D., President & CEO of Onconova, will present at the conference.

Where is the Ladenburg Thalmann 2022 Healthcare Conference being held?

The conference is taking place at the Sofitel Hotel in New York, NY.

How can I view Onconova's presentation?

The presentation can be viewed online via Onconova's website and will be archived for 90 days.

What are Onconova's current clinical studies focused on?

Onconova's studies focus on the multi-kinase inhibitor narazaciclib and rigosertib for cancer treatments.